



10TH CONGRESS OF THE EUROPEAN SOCIETY OF CONTRACEPTION

PRAGUE, CZECH REPUBLIC, APRIL 30 - MAY 3, 2008

Non-contraceptive impact of contraception and family planning

Under the Patronage of the Mayor of Prague

Final programme





Dear Colleagues and Friends,

Allow us to welcome you again in Prague for the 10th Congress of the European Society of Contraception (ESC) in the Prague Congress Centre. Its unique position, on the top of one of the Prague hills, overlooks the city. The Center offers a beautiful view of the famous Prague skyline, with the silhouette of Prague Castle reflected in waters of the Vltava river, as well as beautiful parks, numerous churches, towers, palaces and ancient historic buildings of the city center.

The Congress Scientific Committee received many valuable suggestions for topics and speakers. After careful consideration of all these suggestions, the committee has drafted the scientific programme, bringing together current topics and excellent speakers. To make the programme even more attractive, a considerable proportion is interactive, including meet the expert sessions, workshops and fora. For the first time, each ESC Expert Group is organising its own session, and young scientists also have their own session.

Prague, the capital of the Czech Republic, is a great place to visit. In the Middle Ages it was considered one of the most beautiful cities of the world, receiving attributes like „golden Prague“ or „city of a hundred towers“. Today Prague contains one of the largest collections of historic sights, with a mixture of Romanesque, Gothic, Renaissance, Baroque, Art Nouveau and Cubist architecture.

Enjoy not only the Congress' scientific programme, but also the hospitality of our people and the atmosphere of the „golden City“. We are confident that the upcoming 10th ESC Congress, as well as Prague itself, will stay in your memory for a long time.

Sincerely Yours,



David Cibula

President of the European Society of Contraception
and Congress President



Vit Unzeitig

Vice President of the
10th ESC Congress

Organization

Executive Committee of the ESC

D. Cibula (President)
D. Lazaris (Vice President)
O. Loeber (Secretary General)
G. Bartfai (Assistant Secretary)
M. Lech (Treasurer)
S. Özalp (Assistant Treasurer)

Board of Directors

J.J. Amy (Belgium)
D. Apter (Finland)
G. Bartfai (Hungary)
I. Batar (Hungary)
A. Bigrigg (United Kingdom)
J. Bitzer (Switzerland)
I. Blidaru (Romania)
T.A. Carmo Bombas (Portugal)
D. Cibula (Czech Republic)
P.G. Crosignani (Italy)
G. Crvenkovic (Croatia)
V. Cupanik (Slovakia)
D. Lazaris (Greece)
M. Lech (Poland)
I. Lete (Spain)
O. Loeber (The Netherlands)
E. López Arregui (Spain)
C. McNicholas (Ireland)
H. Missey Kolb (France)
M. Orlean (Latvia)
S. Özalp (Turkey)
B. Pehlivanov (Bulgaria)
K. Petersen (Denmark)
B. Pinter (Slovenia)
V. Prilepskaya (Russia)
T. Rabe (Germany)
S. Randall (United Kingdom)
C. Riris (Cyprus)
V. Sadauskas (Lithuania)
N. Salakos (Greece)
H. Satiroglu (Turkey)
K. Sedlecki (Serbia)
V. Unzeitig (Czech Republic)
A. Yeshaya (Israel)

International Scientific Committee

D. Apter (Finland)
I. Batar (Hungary)
R. Beerthuizen (The Netherlands)
J. Bitzer (Switzerland)
A. Cagnacci (Italy)
D. Cibula (Czech Republic), Chair
K. Gemzell – Danielsson (Sweden)
G. Lazdane (WHO)
I. Lete (Spain)
S. Özalp (Turkey)
J. Paavonen (Finland)
S. Randall (United Kingdom)
R. Sitruk-Ware (USA)
S. Skouby (Denmark)
V. Unzeitig (Czech Republic)

Organizing Committee

D. Cibula (Czech Rep.), President
V. Unzeitig (Czech Rep.), Vice President
O. Loeber (The Netherlands), Assistant Secretary
M. Fanta (Czech Rep.), Treasurer
M. Lech (Poland), Assistant Treasurer
M. Kostal (Czech Rep.), Member
P. Krepelka (Czech Rep.), Member
R. van Lunsen (The Netherlands), Member
P. Weiss (Czech Rep.), Member

Congress secretariat

ESC Central Office
Opalfeneweg 3
1740 Ternat, Belgium
Tel. +32 2 582 08 52
Fax +32 2 582 55 15
esccentraloffice@contraception-esc.com
www.contraception-esc.com

Highlights

Young Scientists

A Young Scientist session will provide a special platform for presentations by young scientists (below 33 years of age). Each presenter in this session will compete for the ESC Young Scientist Prize.

Awards

Besides the ESC Best Poster, the ESC Best Public Poster, and ESC Young Scientists Award, the ESC Medal will be awarded for the second time to honour a member for his/her outstanding scientific work and/or organizing activity performed in accordance with the aims of the Society.

Training and education

The programme will ensure the educational aims of the congress through specific sessions and tools.

Workshops and fora

Fora will be organized as interactive sessions, introduced by two experts in the field and followed by an in depth discussion with the audience. A workshop will teach participants how to search for information, carry out research and write a paper.

Society sessions

Some slots are dedicated to other Societies with aims similar to the ESC.

Expert meetings

Informal, round-table discussions during lunch with a maximum of 15 participants.

Sessions of ESC Expert Groups

The newly established Expert Groups are each organising their own sessions for the first time and will focus on the highlights in their area of expertise.

High standard scientific programme

The Scientific Committee has endeavoured to put together a high standard, well balanced scientific programme, offering current topics and excellent speakers. To make the programme even more attractive, a considerable proportion will be interactive with the audience.

Simultaneous translation into Russian and French will be provided during all plenary sessions, congress sessions and keynote lectures.



Scientific programme

The scientific programme covers all aspects of reproductive health and contraception from basic good practice to the most up to date research.



Keynote lectures are plenary sessions which are scheduled for 30 minutes. Leading experts will present specific subjects.

Each congress day starts with a **plenary session** during which no parallel activity is scheduled. An international panel of experts will critically assess the state of scientific knowledge pertaining to a specific topic.

Congress sessions (State of the art) : in each of these 6 sessions, three or four experts will provide up to date information on a topic, with plenty of opportunity for questions. There will be two selected free communications added to each session.

Fora are meant as interactive sessions, introduced by two experts in the field and followed by a discussion with the audience.

A workshop will teach participants how to search for information, carry out research and write a paper on contraception and will be managed by J.J. Amy (Belgium), Editor-in-Chief of the European Journal of Contraception and Reproductive Health Care (EJCRHC) and K. Patrick (UK), Associate Editor of the BMJ.

Meet the Expert sessions are scheduled on Thursday and are organised as informal, round table discussions during lunch with a maximum of 15 participants. A variety of topics will be covered. Participants will receive a free lunch box. **Please register at the registration desk for these meet the expert sessions.**

Working groups sessions are planned on Friday lunch time. They are organized by five newly established ESC Expert Groups. The format of the sessions may differ from each other.

Society sessions are organized by national and international societies or organizations and will discuss a specific item within their area of interest. Society sessions may be organized in a language other than English.

Continuing Medical Education Credits



Approval of the Congress programme for continuing medical education (CME) credits have been applied for with the European Accreditation Council for Continuing Medical Education (EACCME). The EACCME is an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). All faculty and other speakers at this scientific event are aware of, and have agreed, to sign the UEMS/EACCME disclosure form, and have disclosed any potential conflict of interest that they may have.

Symposia will be the platform for the pharmaceutical companies.

Free Communication Sessions : a selection of the submitted free communications are either integrated into the congress sessions or scheduled into separate free communications sessions. All abstracts submitted have been subject to peer review. Abstracts of selected free communications can be found in the Book of Abstracts.

A Young Scientist session aims to provide a special platform for paper presentations by young scientists. The session is primarily targeted at Fellows and Ph.D. students, but the only inclusion criterion was the age, < 33 years. The ESC Young Scientist Prize, sponsored by Organon, a part of Schering-Plough Corporation, will be awarded during the Closing Ceremony on Saturday.

Posters are chosen from the submitted abstracts and displayed in the Congress Hall Foyer, 2nd floor, grouped by topic. Posters will carry equivalent scientific status to free communications in the programme. Abstracts of selected posters can be found in the Book of Abstracts. The poster area

is on level 2 - Congress Hall Foyer. Posters will be on display for the full time of the Congress and can be mounted on Wednesday 30 April, between 12:00 and 19:00. Contact the Poster Manager for assistance.

Best Poster Session

Authors should be at their poster during coffee breaks. A selection of the best posters will be presented in the Best Poster Session on Friday afternoon 2 May from 14:30 to 15:30.

Poster presentators should check on Friday (latest at 12:00) if their poster has been selected by looking for a balloon on your posterboard. Those selected will have to prepare a presentation for the Best Poster Session on Friday Afternoon from 14:30 to 15:30. The talk should be limited to 5 minutes, documented with a maximum of 5 Powerpoint slides. Poster presentors are asked to submit their presentation to the preview room as soon as possible.

The Best Poster Prize (sponsored by Organon, a part of Schering-Plough Corporation) will be awarded during the Closing Ceremony on Saturday.

The ESC Best Public Poster is supported by an unrestricted educational grant from Bayer Schering Pharma

In your personal envelope (a.o. containing your badge), you will find two voting ballots. Please indicate on each ballot a poster number you would like to nominate. Since you have two ballots, you can nominate two different posters. Please drop both ballots in the poster voting bin in the registration area. The ESC Best Public Poster Prize will be awarded during the Closing Ceremony on Saturday.

Participants are encouraged to return their completed ballots: one ballot will be drawn randomly and this participant will take a crystal vase from Moser Company home.

Assembly of ESC Members (ESC General Assembly)

Friday, 2 May, 16:30-18:00 (Congress Hall).

Only members of the European Society of Contraception who paid their membership fee for the year 2008 will have access to the General Assembly. If your membership fee is not paid yet, you can still do so at the registration desk, until Friday 2 May at noon (12:00h).

Badges

Congress badges should be worn by all participants at all times during the congress and while visiting the exhibition area. No badge, no entry!

Badges are colour-coded as following:

- Participants: ESC-members: White
- Participants: non members: Red
- Exhibitors: Blue
- Organisers and staff: Yellow

Book of abstracts

You will find the book of abstracts in your congress bag. Additional copies can be purchased at the congress registration desk.

Currency

The Czech currency is called the Czech crown (1 EURO = +- 25,4 CZK).

Certificate of attendance

A Certificate of attendance will be available in your personal envelope and will be delivered together with your badge upon arrival.

Congress venue

Prague Congress centre
5.kvetna 65, 140 21 Prague 4, Czech Republic
<http://www.kcp.cz>

Eating & Drinking

No lunch facilities are organised by the Congress. Participants who register for a 'Meet the Expert' session do have a lunch box included. Free lunches will be provided to delegates attending the Sponsored Symposium on Thursday lunchtime. Free lunches will be provided

to delegates attending the Working Group Sessions (Friday, Lunchtime). There are a number of lunch facilities in the vicinity of the PCC (Holiday inn, Corinthia Towers, Rio's Restaurant Vysehrad, Restaurace Summa Arc, Pizza-Restaurant Lucky Luciano, Restaurace Sklenik)

Electricity

Electrical systems are 220/230 volts AC 50 HZ. Adaptors for plugs may be necessary.

Evaluation forms

In order to allow the organisers to learn from past experiences they would be very grateful if you would be willing to give them the necessary feedback.

1. You may be asked by someone from the organisation to take part in a short interview related to the organisation.
2. You will receive an evaluation form when entering a session room, facilitating the evaluation of that particular session. Kindly complete the form and return it to the hostess when leaving the room.

The congress organisers appreciate your valuable feedback.

Exhibit and sponsors

See also 'exhibit and sponsors' later in this book. The exhibition area is situated on the second floor. Coffee breaks will be served in the exhibition area. Delegates are encouraged to visit the stands and to recognise the valuable support which these companies have provided towards the congress.

Hotel accommodation and tours for participants

Guarant is in charge of all hotel reservations and tours for groups and will have an accommodation desk within the registration area of the PCC with the aim to help you with any questions related to accommodation and tours.

Guarant International spol s.r.o.
Opletalova 22
110 00 Prague 1
Czech Republic
T. +420 284 001 444
F. +420 284 001 448

Insurance, liability

ESC does not accept liability for individual medical, travel or personal insurance, and participants are strongly advised to take out their own personal insurance policies in their country of origin.

Language

The official language of the congress will be English. Simultaneous translation is foreseen into **Russian and French**. Some of the Society sessions might be held in the language of the organizing country.

Meet the Expert sessions

Meet the Expert sessions are organised on Thursday, from 12:30 -13:30. Attendance to those sessions is limited to 15 persons maximum. Please register at the registration desk for these meet the expert sessions.

Meeting point

Should you wish to arrange to meet someone, the official meeting point is indicated as 'Meeting point' in the registration area.

Message desk

Messages will be on display in the registration area on a special dedicated board

Posters

See section 'Scientific Programme'

Preview room for invited speakers

Speakers are kindly invited to submit their slides - either on CD-rom, memory stick or



laptop - at least 60 minutes before their presentation to the preview room, and before their session starts. Last minute preview facilities will be available. The preview room is situated on level 2, room 2.1.

Prague public transport (www.dp-praha.cz)

The capital city of Prague has a widespread network of public transport routes which include bus, tram and metro links. Bus and tram timetables are harmonized with metro connections. The metro operates from 5 am until midnight. Time intervals in peak-hours of week days are 2 to 4 minutes, off-peak hours 4 to 10 minutes. Trams operate daily between 4,30 am and 00,15 am, night tram services have numbers from 51 to 58 and run from 00.15 am until 4.30 am. Central changing tram stop is Lazarská stop. The relevant timetable is available at each stop.

Tourist information

There is an information desk within the registration area of the Congress venue to help you with tourist information.

History

Prague is the most beautiful Czech historical city. It came into existence as a town when, after 870, Prague Castle was built. In the 11th century, the first Czech king, Vratislav I, chose Prague as his capital. The city has always played an important part in the history of the nation, country and Europe. Since medieval times, Prague has been known as one of the most beautiful cities in the world.

Down the centuries, major cultural and political personalities have paid homage to Prague; W. A. Mozart, L. van Beethoven, F. M. Dostoyevski, A. Rodin, O. Kokoschka, Queen Elisabeth II and John Paul II., just to name a few, have allowed the spirit and beauty of the city to enchant them. Its atmosphere has been reflected in the works of world-class artists, e.g. Alfons Mucha, Franz Kafka, Max Brod, Jan Neruda, Jaroslav Hasek, Jaroslav Seifert or Egon Erwin Kisch. Prague is not only the centre of cultural movements dating back centuries; it also exhibits a unique collection of historical monuments, dominated by Prague Castle. Art from every period in history can be found here. Prague occupies both banks of the Vltava River and consists of 6 districts: Old Town, Josefov (the part of Jewish town which is still preserved today - currently a part of Old Town), New Town, Lesser Town, Hradcany and Vysehrad. These districts host the majority of historical landmarks, museums and galleries. Prague has nearly 1,2 million inhabitants. In 1348 the Charles University was founded as one of the oldest universities in Europe. In 1992, the historical core of the city (866 hectares) was listed in the UNESCO World Cultural and Natural Heritage Register, as a town with a unique and lively blend of roman, gothic, renaissance, baroque, Art Nouveau and cubist architecture.

Registration

Registration package

The registration package for the participants includes:

- admission to the scientific sessions and the exhibition area
- access to the opening ceremony
- abstract book
- final programme
- certificate of attendance
- coffee and tea during breaks
- welcome cocktail (Wednesday April 30, 2008)

Opening hours of the registration desk

| | |
|---------------------|---------------|
| Wednesday, April 30 | 12:00 - 19:00 |
| Thursday, May 1 | 08:00 - 18:00 |
| Friday, May 2 | 08:00 - 18:00 |
| Saturday, May 3 | 08:00 - 12:00 |

On-site registrations (Prices include 19% Czech VAT)

All payments are payable in EURO Amount to pay

| | |
|--|-----|
| ESC members | 630 |
| Non-members | 730 |
| Students and nurses* | 420 |
| Czech and Slovak participants | 630 |
| Congress Dinner** | 100 |
| Extra person (besides yourself) attending the Opening Ceremony and Cocktail | 40 |

* Status must be evidenced by a written employers' statement or copy of certificate.

** Participants who have not booked their dinner ticket in advance, can ask at the registration desk to see whether there are tickets left.

Wednesday, April 30, 2008

Opening Ceremony (18:00) and Welcome Reception (19:00)

All participants and their extra persons are warmly invited to join us for the Opening Ceremony that will take place in the Congress Hall of the Prague Congress Centre. It will be an entertaining and eventful introduction to the congress. During the ceremony, the ESC Medal will be awarded for the second time. At the end of the opening ceremony, there will be a music and dancing folklore show presented by the Military Artistic Ensemble ONDRÁŠ. After the Opening Ceremony, we will officially open the industrial exhibition and invite our delegates to the Welcome Reception. Attendance at the Opening Ceremony and Welcome Reception are complimentary.

Thursday, May 1, 2008 (18:15 - Hall IV)

Movie night - 4 Months, 3 Weeks and 2 Days

4 Months, 3 Weeks and 2 Days, winner of the grand prize at the 2007 Cannes Film Festival, is set in Communist Romania, in the 1980s, with boxy Eastern Bloc autos, ill-lit streets, and a thriving black market: Kent cigarettes, Tic-Tacs, abortions. Like various forms of contraception, abortion was illegal under the regime of Nicolae Ceausescu - totalitarian measures to boost the country's population. And so, in the haunting 4 Months, 3 Weeks and 2 Days, a pregnant college student and her dorm-mate arrange for an illegal termination - to be performed in a drab hotel, by a guy carrying his devices, and his rubber gloves, in a cheap attache case.



Friday, May 2, 2008

Congress Dinner (pre-registration was necessary)

The 10th ESC Congress will not only be about science, but also about having a good time. We offer an exquisite blend of excellent food and entertainment (including dancing) at the "Palác Zofin", a wonderful neorenaissance palace located on the most beautiful island in Prague, "Slovansky ostrov" (Slavic Island), just next to the National Theatre with a view on the Charles bridge and Prague castle. The meeting venue for the dinner is the Prague Congress Centre. The buses will leave at 19:30. The dinner will finish at 24:00 and return transfer to the hotels will be arranged.

Saturday, May 3, 2006 (12:00)

Closing and Award Ceremony

The Closing and Award Ceremony will be held after the last session of the congress. During this Ceremony, the winner of the 2008 ESC Poster Award, the ESC Best Public Poster as well as the winner of the First Young Scientist Award will be presented. At the end of the Ceremony we will say goodbye and make a new appointment for our next congress in The Hague (The Netherlands) in the year 2010.

Friday, May 2

| | <i>Congress Hall</i> | <i>Meeting Hall I</i> | <i>Panorama Hall</i> | <i>Hall IV</i> | <i>Club E</i> |
|---------------|---|--|---|--|--|
| 08:30 | Plenary Session 2 Sexual medicine for FP professionals | | | | |
| 10:00 | Break and poster viewing | Break and poster viewing | Break and poster viewing | Break and poster viewing | Break and poster viewing |
| 10:30 | Sponsored Symposium 3 Gritenthal | Congress Session 4 Do guidelines lead to any change? (WHO session) | Forum 2 Sexual education, sexual health training | Society Session 5 Spanish Society of Contraception | Free Communications 4 |
| 12:00 | Lunch 12:00 - 13:30 | Lunch 12:00 - 13:30 | Lunch 12:00 - 13:30 | Lunch 12:00 - 13:30 | Lunch 12:00 - 13:30 |
| 12:15 - 13:15 | Expert group on sexual and reproductive health and education | | Expert group on non-hormonal methods of contraception | | Expert group on hormonal contraception |
| 13:30 | Keynote 2 Risk of DVT with new molecules | | | | |
| 14:00 | Sponsored Symposium 4 Bayer Schering Pharma | Congress Session 5 Induced abortion : An update | Late Breaking News (14:00-14:30) Best Poster Session (14:30 - 15:30) | Forum 3 What is required before prescribing | Society Session 6 Italian Society of Contraception |
| 15:30 | Keynote 3 Developments in contraception | | | | |
| 16:00 | Break and poster viewing | Break and poster viewing | Break and poster viewing | Break and poster viewing | Break and poster viewing |
| 16:30 | General Assembly | | | | |

Saturday, May 3

Congress Hall

08:30 **Plenary Session 3** : Hormones and breast cancer

10:00 Break

10:30 **Congress Session 6** : Contraception for medically compromised women

12:00 **Closing session**

Wednesday, April 30

Congress Hall

18:00 **Opening Session**
19:00 **Opening Reception (Congress Hall Foyer - 2nd Floor)**

Thursday, May 1

Congress Hall

Meeting Hall I

Panorama Hall

Hall IV

Club E

08:30

Plenary Session 1
Non-contraceptive medical benefits

10:00

Break and poster viewing

Break and poster viewing

Break and poster viewing

Break and poster viewing

Break and poster viewing

10:30

Sponsored Symposium 1
Bayer Schering Pharma

Congress Session 1
Critical evaluation and clinical management of side effects

12:00

Lunch
12:00 - 14:00

Lunch
12:00 - 14:00

Lunch
12:00 - 14:00

Lunch
12:00 - 14:00

Lunch
12:00 - 14:00

12:30

Sponsored Symposium
Bayer Schering Pharma

Meet the Expert Sessions (12:30 - 13:30) - Please check the schedule on the night

14:00

Sponsored Symposium 2
Organon, a part of Schering-Plough Corporation

Congress Session 2
Screening and management of STI in family planning

Free Communications 2

Society Session 3
FIAPC

Society Session 4 (part 1)
Francophone Society of Contraception

15:30

Break and poster viewing

Break and poster viewing

Break and poster viewing

Break and poster viewing

Break and poster viewing

16:00

Keynote 1
HPV Vaccination

16:30

Congress Session 3
Intrauterine contraception

Forum 1
Use and influence of internet

Free Communications 3
Young Scientists

Workshop
Writing a paper on contraception

Society Session 4 (part 2)
Francophone Society of Contraception

Meet the Expert sessions

Room 220

1. Emergency contraception
E. Aubrey (France) - G. Banfiat (Hungary)
Room 223

2. Adolescent Sexuality, Contraception and STD's
G. Craxios (Greece) - H. Salmaglu (Turkey)
Room 224

3. STI

J. Paavonen (Finland)

Room 225

4. Metabolism

S. Skatby (Denmark)

Room 241

5. OC: regimen

M. Kshien (UK)

Room 243

6. Progressins and antiprogestins

R. Strick-Morre (USA) - Ph. Bouchard (France)

Room 244

7. IUD: misconceptions

D. Seifidy (France) - I. Balaz (Hungary)

Room 248

8. Oncology

C. Coll (Spain) - D. Lazaris (Greece)

Club C

9. Sexual satisfaction as major determinant of contraceptive compliance
R. van Lamsen (The Netherlands)

The code next to the time schedule refers to the number in the book of abstracts.

Wednesday, April 30

18:00 Congress Hall

Opening Session

Welcome address by the ESC and Congress President

D. Cibula (Czech Rep.)

Welcome address by the Mayor of Prague

P. Bem (Czech Rep.)

Welcome address by the Dean of the Medical Faculty,
Charles University

T. Žima (Czech Rep.)

ESC Award, introduction

D. Lazaris (Greece)

***Music and dancing folklore show presented
by the Military Artistic Ensemble ONDRAŠ***

19:00 2nd floor Congress Hall Foyer

Opening Reception



Thursday, May 1

- 08:30 - 10:00** Congress Hall **Plenary Session 1**
Non-contraceptive medical benefits
 Chair: M. Lech (Poland) - M. Fanta (Czech Rep.)
- 08:30 • IS-01 Metabolic benefits
S. Skouby (Denmark)
- 09:00 • IS-02 Menorrhagia
R. Hurskainen (Finland)
- 09:30 • IS-03 Cycle-related symptoms
I. Milsom (Sweden)
- 10:00 - 10:30** **Break and poster viewing**
- 10:30 - 12:00** Congress Hall **Sponsored Symposium (Bayer Schering Pharma)**
The premenstrual symptomatology from different angles
 Chair: S. O'Brien (United Kingdom)
- 10:30 Etiology, diagnostic and treatment rationale : International consensus on PMS/PMDD
S. O'Brien (United Kingdom)
- 11:00 PMS/PMDD in real life
A. Schwenkhagen (Germany)
- 11:30 A new oral contraceptive with two additional indications – experiences from the United States
L. Schulman (USA)
-
- 10:30 - 12:00** Meeting Hall I **Congress Session 1**
Critical evaluation and clinical management of side effects
 Chair: D. Cibula (Czech Rep.) - K. Sedlecki (Serbia)
- 10:30 • IS-04 Mood changes/depression
R. van Lunsen (The Netherlands)
- 10:50 • IS-05 Weight changes
M. Lech (Poland)
- 11:10 • IS-06 Bone Mineral Density (BMD)
D. Cibula (Czech Rep.)
- 11:30 • IS-07 Breakthrough bleeding
TBD
- 11:45 • FC-01 How often and why do women discontinue their contraceptive method? Results from a French population-based survey
C. Moureau (France)
- 11:53 • FC-02 Comparison of patients from high risk population with vs. without thrombotic events while exposed to hormonal contraception
M. J. Carvalho (Portugal)
-

| | | |
|---------------|----------------------|---|
| 10:30 - 12:00 | <i>Panorama Hall</i> | <p>Society Session 1 Faculty of Sexual and Reproductive Healthcare (FSRH - UK) European Contraception Masterclass - Transnational Evidence-Based Contraceptive Practice Chair: A. Glasier (UK) - C. Wilkinson (UK)</p> |
| | 10:30 | Opening remarks by the FSRH President <i>M. Kishen (UK)</i> |
| | 10:40 • SS1-01 | Depo-Provera and bone density <i>D. Mansour (UK)</i> |
| | 11:00 • SS1-02 | Intra-uterine devices and infection risk <i>F. Martínez (Spain) - E. Lopez Arregui (Spain)</i> |
| | 11:20 • SS1-03 | Emergency contraception – over the counter and advance supplies <i>I. Batar (Hungary)</i> |
| | 11:40 • SS1-04 | WHO-Medical eligibility criteria in the UK <i>A. Kubba (UK)</i> |
| | 11:55 | Concluding remarks from the Chairpersons |
| <hr/> | | |
| 10:30 - 12:00 | <i>Hall IV</i> | <p>Free Communication Session 1 Chair: P. Kascak (Slovakia) - D. Apter (Finland)</p> |
| | 10:30 • FC-03 | Review of emergency re-admissions after 1st trimester abortion; Implications for service design and delivery <i>O. Graham (UK)</i> |
| | 10:43 • FC-04 | Which women are at risk for repeated abortion? <i>S. Tschudin (Switzerland)</i> |
| | 10:56 • FC-05 | Widening access for practitioners in Scotland to Sexual and Reproductive Health education through e-learning delivery: could this be developed for use in other countries? <i>N. Graham (UK)</i> |
| | 11:09 • FC-06 | Ten years of medical abortion services and innovations in Tunisia <i>S. Hajri (Tunisia)</i> |
| | 11:22 • FC-07 | How do men with subnormal semen values react to hormonal male contraception? <i>E. Nieschlag (Germany)</i> |
| | 11:35 • FC-08 | Contraceptive failure related to early ovulation <i>E. Wiebe (Canada)</i> |
| | 11:48 • FC-09 | Supporting primary healthcare professionals providing crisis pregnancy care in Ireland <i>N. Kenny (Ireland)</i> |
| <hr/> | | |
| 10:30 - 12:00 | <i>Club E</i> | <p>Society Session 2 Association of Reproductive Health Professionals (ARHP - USA) Translating science into practice: helping patients understand health risks for effective, customized care Co-moderators: L. Shulman (USA), A. Furedi (UK)</p> |
| | 10:30 | Opening remarks by the ARHP board chair <i>L. Shulman (USA)</i> |
| | 10:40 • SS2-01 | “You Decide: making informed health choices about hormonal contraception” <i>Co-moderators</i> |

| | | |
|--|-------------------------|---|
| | 11:10 • SS2-02 | “Translating the scientific literature on contraception into effective patient care” <i>Co-moderators</i> |
| | 11:40 | Questions, answers, interactive discussion <i>Co-moderators</i> |
| | 12:00 - 14:00 | Lunch and poster viewing |
| | 12:30 - 13:30 | Congress Hall |
| | | Sponsored Symposium (Bayer Schering Pharma) Contraceptive solutions for modern women Lunch will be served for symposium participants Chair: O. Heikinheimo (Finland) |
| | 12:30 | User expectations and satisfaction with Long-Acting Reversible Contraceptives - Results from a Pan-European Study <i>S. Haimovich (Spain)</i> |
| | 12:50 | Use of Mirena in women with pre-existing medical conditions <i>O. Heikinheimo (Finland)</i> |
| | 13:10 | User satisfaction with Yasminelle <i>M. Short (Ireland)</i> |
| | 12:30 - 13:30 | Meet the Expert Sessions (lunchbox included - pre-registration necessary) |
| | <i>Room 220 • IS-08</i> | 1. Emergency contraception <i>E. Aubeny (France) - G. Bartfai (Hungary)</i> |
| | <i>Room 223 • IS-09</i> | 2. Adolescent Sexuality, Contraception and STD’s <i>G. Creatsas (Greece) - H. Satiroglu (Turkey)</i> |
| | <i>Room 224 • IS-10</i> | 3. STI <i>J. Paavonen (Finland)</i> |
| | <i>Room 225 • IS-11</i> | 4. Metabolism <i>S. Skouby (Denmark)</i> |
| | <i>Room 241 • IS-12</i> | 5. OC regimen <i>M. Kishen (UK)</i> |
| | <i>Room 243 • IS-13</i> | 6. Progestins and antiprogestins <i>R. Sitruk-Ware (USA) - Ph. Bouchard (France)</i> |
| | <i>Room 244 • IS-14</i> | 7. IUD: misconceptions <i>D. Serfaty (France) - I. Batar (Hungary)</i> |
| | <i>Room 248 • IS-15</i> | 8. Oncology <i>C. Coll (Spain) - D. Lazaris (Greece)</i> |
| | <i>Club C • IS-16</i> | 9. Sexual satisfaction as major determinant of contraceptive compliance <i>R. van Lunsen (The Netherlands)</i> |
| | 14:00 - 15:30 | Congress Hall |
| | | Sponsored Symposium 2 (Organon, a part of Schering-Plough Corporation) Non-oral contraceptives: diverse choices and improved patient satisfaction Chair: I. Milsom (Sweden) |
| | 14:00 • SPS2-01 | Contraception: Women’s Attitudes, Expectations and Experiences <i>A. Rieder (Austria)</i> |

- 14:30 • SPS2-02 Novel Non-oral Contraceptives: Expanding Women's Choices
A. Burke (USA)
- 15:00 • SPS2-03 Non-oral Contraceptives: Benefits beyond Contraception
I. Lete Lasa (Spain)

14:00 - 15:30 Meeting Hall I

Congress Session 2

Screening and management of STI in family planning

Chair: V. Unzeitig (Czech Rep.) - T. Bombas (Portugal)

- 14:00 • IS-17 WHO Global STI epidemiology update
G. Lazdane (WHO, Copenhagen)
- 14:20 • IS-18 Testing for STIs in family planning setting - How to make it simple?
A. Brown (UK)
- 14:40 • IS-19 Guidelines for HPV DNA testing - To test or not to test?
H. Kütchener (UK)
- 15:00 • IS-20 Genital Chlamydial Infection: has the risk for tubal factor infertility and adverse pregnancy outcome been exaggerated?
Ĵ. Land (The Netherlands)
- 15:15 • FC-10 To screen or not to screen...are current guidelines for screening all women for Chlamydia under age 25 being followed in primary care and at family planning clinics?
N. Mullin (UK)
- 15:23 • FC-11 First sex: an opportunity of a lifetime for HIV/AIDS prevention
M. Fontes (UK)

14:00 - 15:30 Panorama Hall

Free Communication Session 2

Chair: S. Randall (UK) - J. Paavonen (Finland)

- 14:00 • FC-12 Comparison of corticoid substitution versus combined oral contraception administration in the treatment of nonclassic adrenal hyperplasia (ncah)
M. Fanta (Czech Rep.)
- 14:13 • FC-13 Using of transdermal hormonal contraception by women with a scar on the uterine
O. Gorbunova (Ukraine)
- 14:26 • FC-14 Factors affecting awareness about emergency contraception among college students of Kathmandu, Nepal
R. Adhikari (Nepal)
- 14:39 • FC-15 Evaluation of reproductive health training of soldiers at the first army of Turkish armed forces
B. Bakir (Turkey)
- 14:52 • FC-16 The value of a holistic approach to Family Planning Clinics and Youth Clinics from a public health perspective
I. Lindh (Sweden)
- 15:05 • FC-17 Evaluation of contraceptive activity of some traditional medicinal plants in male rats
P. Chand Mali (India)
- 15:18 • FC-18 Completing abortion safely – how “little” is needed to save lives
O. Simetka (Timor)

| | | |
|---------------|----------------------|--|
| 14:00 - 15:30 | <i>Hall IV</i> | <p><i>Society Session 3</i> <i>International Federation of Professional Abortion and Contraception Associates (FIAPAC)</i> <i>Improving acceptability in induced abortion treatment</i> Chair: M. Parachini (Italy)</p> <p>14:00 • SS3-01 Medical abortion at home <i>E. Aubény (France)</i></p> <p>14:30 • SS3-02 Vacuum aspiration under local anaesthesia <i>C. Fiala (Austria)</i></p> <p>15:00 • SS3-03 Is RH prophylaxis needed? <i>K. Gemzell (Sweden)</i></p> |
| <hr/> | | |
| 14:00 - 15:30 | <i>Club E</i> | <p><i>Society Session 4 (part 1) - Session will be held in French</i> <i>French speaking Society of Contraception (SFC)</i> <i>2ème Séminaire de la Société Francophone de Contraception</i> Présidents: J. Bitzer (Suisse) - M. Bouzckrini (Algérie) U. Gaspard (Belgique) - D. Serfaty (France)</p> <p>14:00 • SS4-01 Nouveaux concepts en contraception orale estroprogestative <i>D. Serfaty (France)</i></p> <p>14:20 • SS4-02 Contraception hormonale transdermique sans patch: rêve ou réalité? <i>R. Sitruk-Ware (USA)</i></p> <p>14:40 • SS4-03 Prévention de la mortalité maternelle: place de la contraception moderne <i>Y. Hyjazi (Guinée)</i></p> <p>15:00 Discussion animée par <i>J. Abboud (Liban), J. Bérubé (Canada), M. Brincat (Malte), H. Chelli (Tunisie), B. Dao (Burkina Faso), N. Homasson (France) - J.C. Moreau (Sénégal)</i></p> |
| 15:30 - 16:00 | | <i>Break and poster viewing</i> |
| 16:00 - 16:30 | <i>Congress Hall</i> | <p><i>Keynote lecture 1</i> Chair: V. Dvorak (Czech Rep.)</p> |
| | IS-21 | <p><i>HPV vaccination</i> <i>J. Paavonen (Finland)</i></p> |
| 16:30 - 18:00 | <i>Congress Hall</i> | <p><i>Congress Session 3</i> <i>Intrauterine contraception</i> Chair: G. Bartfai (Hungary) - C. McNicholas (Ireland)</p> <p>16:30 • IS-22 IUD/IUS in nulliparous women <i>I. Sivin (USA)</i></p> <p>16:50 • IS-23 Management of IUD/IUS in special clinical conditions : emergency contraception, actinomyces, HIV, dysplasia, cancers... <i>D. Serfaty (France)</i></p> <p>17:10 • IS24 Non-contraceptive benefits <i>D. Mansour (UK)</i></p> |

- 17:30 • IS25 Long-term use /use beyond recommended time
I. Batar (Hungary)
- 17:45 • FC-19 The Swing IUS: innovative design for intrauterine contraception
O. Shawki (Egypt)
- 17:53 • FC-20 Contraception in the postnatal period
O. Tanko (Ukraine)

Meeting Hall I
IS-26

Forum 1

Internet: use of internet to promote sexual health and influence on the sexual behaviour of teenagers

S. van der Doef (The Netherlands) - C. Picavet (The Netherlands)

16:30-18:00

Panorama Hall

**Free Communication Session 3 -
Session of the Young Scientists**

Chair: V. Unzeitig (Czech Republic) - G. Lazdane (WHO)

- 16:30 • FC-21 Deciding on abortion – an illusion of power - in depth interviews with Swedish teenage girls three weeks after abortion
M. Ekstrand (Sweden)
- 16:43 • FC-22 Induced abortion on request: who, how and what comes next?
A. Lebre (Portugal)
- 16:56 • FC-23 Assessing the quality of service provided by a community-based vasectomy unit - the consumer viewpoint
S. Moses (UK)
- 17:09 • FC-24 Pharmacies as a source of youth reproductive health care
E. Kikatumidze (Georgia)
- 17:22 • FC-25 Women's knowledge about family planning methods
C. Lopez-delBurgo (Spain)
- 17:35 • FC-26 Youth knowledge, beliefs and behaviour about sexually transmitted infections and condom use
M. Teixeira (Portugal)
- 17:48 • FC-27 Evaluation of an intervention designed to improve adolescent contraceptive use
K. Brown (UK)

16:30-18:00

Hall IV

Workshop

Seeking information, doing research and writing a paper on contraception

- IS-27 Editor-in-Chief of the EJCRC
J.J. Amy (Belgium)
- IS-28 Associate Editor of the BMJ
K. Patrick (UK)

| | | |
|--------------------|----------------|---|
| 16:30-18:00 | <i>Club E</i> | <i>Society Session 4 (part 2) - Session will be held in French French speaking Society of Contraception (SFC) 2ème Séminaire de la Société Francophone de Contraception</i> Présidents: E. Guilbert (Canada) - M. Traoré (Mali) - M. Yacoubi (Maroc) |
| | SS4-04 | L'os et la contraception hormonale estro-progestative et progestative <i>C. d'Arcangues (OMS)</i> |
| | SS4-05 | Pilule et libido: toutes les pilules sont-elle équivalentes? <i>R. van Lunsen (The Netherlands)</i> |
| | SS4-06 | Intérêt de l'estétrol, nouvel estrogène d'origine foetale, en contraception <i>Ph. Bouchard (France)</i> Discussion animée par <i>R. Dreyfus (France), U. Gaspard (Belgique), B. Guifo-Tagné (Cameroun), N.D. Hinh (Vietnam), N. Ogowet-Igumu (Gabon), Ch. Welffens-Ekra (Côte d'Ivoire)</i> |
| 18:15 | <i>Hall IV</i> | <i>Movie night - 4 Months, 3 Weeks and 2 Days</i> |

Friday, May 2

| | | |
|----------------------|-----------------------|---|
| 08:30 - 10:00 | <i>Congress Hall</i> | <p><i>Plenary Session 2</i> <i>Sexual medicine for family planning professionals</i> Chair: R. van Lunsen (The Netherlands) - P. Weiss (Czech Rep.)</p> |
| 08:30 • IS-29 | | Passion, love and relationship <i>A. Vansteenkoven (Belgium)</i> |
| 09:00 • IS-30 | | Hormones and sexual behaviour <i>R. Nappi (Italy)</i> |
| 09:30 • IS-31 | | Sexual problems in the family planning consultation - what to do <i>J. Bitzer (Switzerland)</i> |
| 10:00 - 10:30 | | <p><i>Break and poster viewing</i></p> |
| 10:30 - 12:00 | <i>Congress Hall</i> | <p><i>Sponsored Symposium 3 (Grünenthal)</i> <i>Oral contraception and women's wellbeing</i> Chair: P. Krepelka (Czech Republic)</p> |
| SPS3-01 | | Oral contraception and hyper androgenic disturbances of skin and hair <i>H. Wölff (Germany)</i> |
| SPS3-02 | | Cosmetic benefits of oral contraceptive – Relevance for QoL and psychosocial health <i>M. Kerscher (Germany)</i> |
| SPS3-03 | | CMA/EE – Improvement of women's wellbeing <i>R. Druckmann (France)</i> |
| SPS3-04 | | CMA/EE – Relief of dysmenorrhoea symptoms and mood balancing effects <i>H.P. Zähradnik (Germany)</i> Discussion |
| <hr/> | | |
| 10:30 - 12:00 | <i>Meeting Hall I</i> | <p><i>Congress Session 4 (WHO special session)</i> <i>Do guidelines lead to any change?</i> Chair: V. Cupanik (Slovakia) - S. Randall (UK)</p> |
| 10:30 • IS-32 | | The WHO family planning cornerstones: a living testimony to the power of partnership <i>P. van Look (WHO, Geneva)</i> |
| 11:00 • IS-33 | | Implementation of family planning guidelines in Europe – adoption and adaptation <i>G. Lazdane (WHO, Copenhagen)</i> |
| 11:30 • IS-34 | | Recommended changes in practice <i>A. Glasier (UK)</i> |
| <hr/> | | |

| | | |
|---------------|-------------------------------|--|
| 10:30 - 12:00 | <i>Panorama Hall</i> IS-35 | Forum 2 Sexual education, sexual health training needs <i>O. Loeber (The Netherlands) - B. Pinter (Slovenia)</i> |
| <hr/> | | |
| 10:30 - 12:00 | <i>Hall IV</i> | Society Session 5 (Session will be held in Spanish) Spanish Society of Contraception Contraceptive and sexual trends in Spain: the work of an active Society Chair: E. Pérez Campos (Spain) |
| | SS5-01 | Reproductive Health Care in Spain: results of several national surveys <i>I. Serrano (Spain)</i> |
| | SS5-02 | Factors affecting the contraceptive choice. A new approach based on Spanish clinical studies <i>I. Lete (Spain)</i> |
| | SS5-03 | Is the menstruation necessary? The point of view of the Spanish women <i>M. Angeles Gómez (Spain)</i> |
| <hr/> | | |
| 10:30 - 12:00 | <i>Club E</i> | Free Communication Session 4 Chair: R. Beerthuisen (The Netherlands) - S. Skouby (Denmark) |
| | 10:30 • FC-28 | Is Misoprostol® a non-surgical alternative to standard surgical care for treatment of incomplete abortion: Answers from a series of clinical trials <i>J. Blum (USA)</i> |
| | 10:43 • FC-29 | The impact of a one-stop abnormal uterine bleeding clinic on the promotion of long-term medical therapies and the consequent reduction of surgical treatments, including hysterectomies, in women suffering from menorrhagia <i>M. Mansour (UK)</i> |
| | 10:56 • FC-30 | Pap-test in IUCD and COCP users. A comparative study in 8920 women. <i>A. Zavalanos (Greece)</i> |
| | 11:09 • FC-31 | The determination of estrous cycle in rats by vaginal lavage <i>M. Gomes Vilela (Brazil)</i> |
| | 11:22 • FC-32 | Prospective follow-up of an extended regimen using oral contraceptive pills containing ethinyl estradiol and drospirenone <i>D. Seidman (Israel)</i> |
| | 11:35 • FC-33 | Open referral system for abortion service is effective and patient friendly <i>J. Amu (UK)</i> |
| | 11:48 • FC-34 | Trend of post-abortion contraceptive choice within an inner city abortion clinic between 1998 and 2006 <i>SSM Wong (UK)</i> |

12:00 - 13:30

Lunch and poster viewing

Working Groups (sessions of the ESC Expert Groups)

12:15 - 13:15 Congress Hall

1. Expert Group on Sexual and reproductive health and education

IS-36

Workshop: Let's talk about sex

Moderators: J. Bitzer (Switzerland) - S. van der Doef (The Netherlands)

12:15 - 13:15 Meeting Hall I

2. Expert Group on STI

Chair: J. Paavonen (Finland)

IS-37

How to maximize health benefits of HPV vaccination?

J. Paavonen (Finland)

IS-38

Selected obstetric and gynecologic aspects of HIV infection

O. Heikinheimo (Finland)

IS-39

Cervical cancer screening is a mess in many European countries: what can we do?

A. Szarewski (United Kingdom)

IS-40

Overall STI incidence trends: future prospects

B. Stray-Pedersen (Norway)

12:15 - 13:15 Hall IV

3. Expert Group on abortion

Workshop: Misoprostol in abortion care

Chair: C. Fiala (Austria) - A. Verougstraete (Belgium)

IS-41

Practical aspects

K. Gemzell (Sweden)

IS-42

Legal aspects

A. Weeks (UK)

12:15 - 13:15 Club E

4. Expert Group on hormonal contraception

Needs and future options in hormonal contraception

Chairman: D. Serfaty (France)

IS-43

Do we need new (natural) oestrogens? / Do we need new progestins?

Speaker: R. Sitruk-Ware (USA) - Commentator: S. Skouby (Denmark)

IS-44

Do we know how to speak to youngsters about sexuality and contraception?

Speaker: J.J. Amy (Belgium) - Commentator: R. Sitruk-Ware (USA)

IS-45

Can a properly chosen hormonal contraceptive help avoiding

the metabolic and cardio-vascular complications of the polycystic ovary syndrome?
Speaker: S. Skouby (Denmark) - Commentator: D. Cibula (Czech Rep.)
 IS-46 What is the carcinogenic risk of combined oral contraceptives and progestogen only contraceptives?
Speaker: D. Cibula (Czech Rep.) - Commentator: J.J. Amy (Belgium)

12:15 - 13:15 *Panorama Hall*

5. Expert Group on non-hormonal methods of contraception

State-of-the-art in non-hormonal contraception

Chair: I. Batar (Hungary) - A. Glasier (UK)

IS-47

Sterilization
R. Beerthuisen (The Netherlands)

IS-48

IUD
I. Swin (USA)

IS-49

Mechanical barriers
S. Brechin (UK)

IS-50

Spermicides
I. Batar (Hungary)

IS-51

Periodic abstinence
G. Freundl (Germany)
 Discussion - Conclusions and practical/clinical suggestions

13:30 - 14:00 *Congress Hall*

Keynote Lecture 2

Chair: P. Krepelka (Czech Rep.)

Risk of DVT with new molecules

O. Lidegaard (Denmark)

14:00 - 15:30 *Congress Hall*

Sponsored Symposium 4 (Bayer Schering Pharma)

New research: important data for counselling your OC patients

Chair: M. Cronin (Bayer Schering Pharma)

Bayer Schering Pharma: Taking a leading role in woman's health research

M. Cronin (Bayer Schering Pharma)

EURAS: the largest European active surveillance study on the safety and efficacy of OC us

J. Dinger (Germany)

Two new major studies on the protective effect of OC use on ovarian and endometrial cancer

TBD

Putting the new data into perspective for your OC patient

L. Shulman (USA)

| | | |
|---------------|-----------------------|--|
| 14:00 - 15:30 | <i>Meeting Hall I</i> | <p>Congress session 5 Induced abortion - An update Chair: V. Prilepskaya (Russia) - J. Bitzer (Switzerland)</p> <p>14:00 • IS-53 The challenge of post-abortion contraception <i>K. Gemzell (Sweden)</i></p> <p>14:20 • IS-54 Follow-up after induced abortion: current practice and evidence <i>C. Fiala (Austria)</i></p> <p>14:40 • IS-55 Access to safe abortion: legal and other obstacles <i>M. Vekemans (United Kingdom)</i></p> <p>15:00 • FC-35 A comparison of two dosages of buccal Misoprostol® following Mifepristone® for early medical abortion <i>T. Tsereteli (Georgia)</i></p> <p>15:15 • FC-36 Expanding options for in-the-mouth Misoprostol® administration following Mifepristone® in medical abortion <i>B. Winkoff (USA)</i></p> |
| <hr/> | | |
| 14:00 - 15:30 | <i>Panorama Hall</i> | <p>Late Breaking News 14:00 Estetrol; a new estrogen in the pill? <i>H. Coelingh Bennink (The Netherlands)</i></p> <p>Best Poster Session 14:30 Best Poster Session</p> |
| <hr/> | | |
| 14:00 - 15:30 | <i>Hall IV</i> | <p>Forum 3</p> <p>IS-57 What is required/minimal criteria/ what should be examined before prescribing <i>D. Apter (Finland) - A. Glaser (UK)</i></p> |
| <hr/> | | |
| 14:00 - 15:30 | <i>Club E</i> | <p>Society Session 6 (Session will be held in English) Italian Society of Contraception Chair: A. Volpe (Italy) - G.B. Melis (Italy)</p> <p>SS6-01 Prevalence of contraceptive use in Italy: comparison with European countries <i>G. Benagiano (Italy)</i></p> <p>SS6-02 Contraception without bleeding. Attitude of Italian women <i>F. Fruzzetti (Italy)</i></p> <p>SS6-03 Changing contraceptive needs in different life stages <i>V. Bruni (Italy)</i></p> <p>SS6-04 Therapeutical effects of hormonal contraceptives <i>P.G. Crosignani (Italy)</i></p> |

- 15:30 - 16:00 *Congress Hall* ***Keynote Lecture 3***
Chair: S. Randall (UK)
- New developments in contraception***
R. Sitruk-Ware (USA)
- 16:00 - 16:30 ***Break and poster viewing***
- 16:30 - 18:00 *Congress Hall* ***ESC General Assembly (members only)***



Saturday, May 3

08:30 - 10:00 Congress Hall

Plenary Session 3

Hormones and breast cancer

Chair: D. Lazaris (Greece) - M. Kostal (Czech Rep.)

08:30 • IS59

Mechanisms
A. O. Mueck (Germany)

09:00 • IS60

Epidemiology
C. LaVecchia (Italy)

09:30 • IS61

Clinical relevance
H. Schneider (Germany)

10:00 - 10:30

Break

10:30 - 12:00 Congress Hall

Congress Session 6

Contraception for medically compromised women

Chair: S. Özalp (Turkey) - H. Missey-Kolb (France)

10:30 • IS-62

Hormonal contraception in women with disorders of carbohydrate metabolism
A. Cagnacci (Italy)

10:50 • IS-63

Hormonal contraception in women with coagulation disorders and thrombophilia
J. Conard (France)

11:10 • IS-64

Hormonal contraception in women with mental diseases
T. Backstrom (Sweden)

11:30 • IS-65

Contraceptive management of women or couples with HIV
S. Källick (UK)

11:45 • FC-37

Etonogestrel implant in women with diabetes
L. Vicente (Portugal)

11:53 • FC-38

Efficacy of levonorgestrel-releasing intrauterine system "Mirena®" in women of advanced maternal age with uterine myoma
L. Suturina (Russia)

12:00 - 12:30 Congress Hall

Closing Session

Chair: D. Cibula (Czech Rep.) - R. Beerhuizen (The Netherlands) - R. van Lunsen (The Netherlands) - S. Randall (UK)

Closing Remarks

Best Poster Award

Young Scientists Award

ESC Best Public Poster Prize

Invitation to the 11th ESC Congress in The Hague (The Netherlands)

Exhibit

The exhibition area is situated on the second floor in the Congress Hall Foyer. Coffee breaks will be served in the exhibition area.

Delegates are encouraged to visit the exhibition stands and to recognise the valuable financial support which these companies have provided towards the congress.

Opening hours exhibit

- Wednesday 30 April 2008 18:00 - 21:00
- Thursday 1 May 2008 08:30 - 18:00
- Friday 2 May 2008 08:30 - 16:30
- Saturday 3 May 2008 08:30 - 10:30

Major sponsors


Bayer Schering Pharma
Grünenthal
Organon, a part of Schering Plough Corporation

Sponsors

Contrel Europe
Eurim-Pharm
Exelgyn
Gedeon Richter
Medgyn products
Prosan International
Wisepress Online Bookshop

Floorplan & exhibit plan

First floor



Meeting Hall 1

Congress Hall


Club E

Registration

Panorama Hall

Second floor

Meeting Hall IV



Overview exhibitors

- | | |
|--------------------------|--|
| 1. Prosan | 7. Organon, a part of Schering Plough Corporation |
| 2. Medgyn Products | 8. 11th ESC Congress, Convention Bureau The Hague |
| 3. Exelgyn | 9. Gedeon Richter |
| 4. Eurim-Pharm | 10. Fiera Milano Congressi |
| 5. Grünenthal | 11. Wisepress Online Bookshop |
| 6. Bayer Schering Pharma | 12. Faculty of Sexual and Reproductive Healthcare (RCOG) |
| | 13. ARHP |
| | 14. MD Communication |

MEMBERSHIP FORM 2008

Join (or renew) the European Society of Contraception (ESC) as a member for the year 2008 by completing and returning this form as mentioned below (full information on www.contraception-ESC.com)

Personal details

Last name (family name) :
First name :
Title :
Institute :
Department :
Street :
Postal code and city :
Country :
Email address :
Telephone number :
Fax number :

Payment section (please tick the appropriate check-box)

Amount due: 50 EURO (including the Journal of Contraception and Reproductive Health Care)

Please charge my credit card Eurocard/Mastercard VISA

- Card N°:.....
- Exp. date:
- CVC code :.....

The Card Verification Code (CVC) Is printed on your MasterCard & Visa cards in the signature area of the back of the card. (it is the last 3 digits AFTER the credit card number in the signature area of the card).

- Name of Cardholder:
- Signature:

I made a bank transfer in EURO to ESC account N° (IBAN) BE45 3101 2639 1389 ING bank, SWIFT code: BBRUBEBB (bank address: ING bank, Marktplein 26, B-1740 Ternat, Belgium) with no costs to the beneficiary



Bayer HealthCare
Bayer Schering Pharma

Inspired by confidence

- Ensures effective and reliable long-acting contraception
- Makes period lighter, shorter and less painful, thus making women feel better



Mirena[®]

Confidence that lasts

Mirena[®] product description: Mirena[®] is a levonorgestrel-releasing intrauterine system (IUS) with an initial release rate of 20 microgram/24 h. Mirena[®] is inserted into the uterine cavity by a trained health professional. One administration is effective for five years. **Indications:** Contraception, idiopathic menorrhagia, protection from endometrial hyperplasia during estrogen replacement therapy. **Contraindications:** Known or suspected pregnancy, current or recurrent pelvic inflammatory disease, lower genital tract infection, postpartum endometritis, infected abortion during the past three months, cervicitis, cervical dysplasia, uterine or cervical malignancy, undiagnosed abnormal uterine bleeding, congenital or acquired uterine anomaly including fibroids

if they distort the uterine cavity, conditions associated with increased susceptibility to infections, acute liver disease or liver tumor, hypersensitivity to constituents of the preparation, progestogen-dependent tumors.

Marketing authorization holder: BAYER SCHERING PHARMA AG (local subsidiary). Corporate address: BAYER SCHERING PHARMA AG, D-13342 Berlin, Germany. For full product information see package insert or consult our scientific literature. Approved indications, price and reimbursement may differ between countries; for further information, please contact the local Bayer Schering Pharma office.

Preparation of the PI: 20-12-2006, preparation of the ad: 20-12-2006.



It's not only a new OC.



Yasminelle® with Drospirenone.

The new 20µg OC with well-known benefits.

Improved emotional and physical well-being.

Yasminelle® Prescribing Information *Indication:* oral contraception. *Composition:* Active ingredients: one light pink film-coated tablet contains 0.02 mg ethinylestradiol (as betadex clathrate) and 3 mg drospirenone. Pharmacologically inactive ingredients: lactose monohydrate, maize starch, magnesium stearate, hypromellose, talc, titanium dioxide (E 171), ferric oxide, red (E 172). *Contraindications:* Yasminelle® is contraindicated, if one of the following conditions is present. Should any of the conditions appear for the first time during COC use, the product should be stopped immediately. Venous thrombosis present or in history (deep venous thrombosis, pulmonary embolism); arterial thrombosis present or in history (e.g. myocardial infarction) or prodromal conditions (e.g. angina pectoris and transient ischemic attack); cerebrovascular accident present or in history; the presence of a severe or multiple risk factor(s) for arterial thrombosis: diabetes mellitus with vascular symptoms, severe hypertension, severe dyslipoproteinemia, hereditary or acquired predisposition for venous or arterial thrombosis, such as APC-resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and anti-phospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant). Pancreatitis or a history thereof if associated with severe hypertriglyceridemia. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. Severe renal insufficiency or acuterenal failure. Presence or history of liver tumours (benign or malignant). Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts). Undiagnosed vaginal bleeding. History of migraine with focal neurological symptoms. Hypersensitivity to the active substances or to any of the excipients of Yasminelle® film-coated tablets. *Side effects:* common side effects reported in clinical trials include emotional lability, headache, abdominal pain, acne, breast pain, breast enlargement, dysmenorrhea, metrorrhagia, weight increase. For uncommon side effects and details see package insert leaflet. *Dosage and regimen:* one tablet is to be taken daily at about the same time for 21 consecutive days, following the order shown on the blister pack. Each sub-sequent pack is started after a 7 day tablet-free interval during which usually a withdrawal bleed occurs. Interactions with other medicinal products: contraceptive failure and breakthrough bleeding have been described for the concomitant use of hydantoin, barbiturates, primidone, carbamazepine and rifampicin. Such interactions are also suspected for oxcarbazepin, topiramate, felbamate, ritonavir, griseofulvin and preparations containing St. John's wort extracts. Contraceptive failure has also been described for concomitant use of antibiotics, such as ampicillin and tetracyclin. *Warnings:* If any of the conditions/risk factors mentioned below is present, the benefits of combined oral contraceptive use should be weighed against the possible risk for each individual woman. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether COC use should be discontinued: Vascular disorders with or without indication of arterial venous thrombosis. The risk is increased for individuals with a respective family history, increasing age, smoking, obesity, dyslipoproteinemia, hypertension, diabetes, immobilization, valvular heart disease, atrial fibrillation, systemic lupus erythematosus, hemolytic-uremic syndrome, chronic inflammatory bowel disease, migraine, sickle cell disease. Tumors: breast cancer risk is slightly elevated for women taking combined oral contraceptives. Breast cancer is rare in women under 40 years of age, and the excess risk potentially caused by hormone intake gradually disappears during the course of the 10 years after cessation of combined oral contraceptive use. Experiences from clinical studies do not provide evidence of a causal relation between the use of combined oral contraceptives and an increased incidence of breast cancer. An increased risk of cervical cancer in long-term users of COCs has been reported in some epidemiological studies. Annual routine checks by a physician are recommended. *Special precautions:* Contraceptive safety is impaired if one or more tablets have been missed. In this case the physician has to be informed. Yasminelle is not indicated during pregnancy. Should a woman become pregnant while taking Yasminelle®, the use has to be terminated immediately. In case of concomitant use of aldosterone-antagonists or potassium sparing preparations the serum potassium level should be tested during the first treatment cycle. Should vomiting and/or severe diarrhea occur within 3-4 hours after the intake of Yasminelle®, a new pill has to be taken. If more than 12 hours have elapsed until the new pill is taken, medical advice has to be sought. Further details see package insert leaflet, valid 22 Feb. 2007.